Mutual of America Capital Management’s Akoustis Technologies Inc AKTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-280,643
Closed -$1.82M 1643
2022
Q1
$1.82M Sell
280,643
-12,208
-4% -$72.6K 0.02% 979
2021
Q4
$1.96M Sell
292,851
-2,736
-0.9% -$20.4K 0.02% 976
2021
Q3
$2.87M Sell
295,587
-4,264
-1% -$40.9K 0.03% 808
2021
Q2
$3.21M Buy
299,851
+65,938
+28% +$697K 0.03% 769
2021
Q1
$3.12M Sell
233,913
-12,898
-5% -$187K 0.03% 769
2020
Q4
$3.02M Sell
246,811
-5,120
-2% -$44.9K 0.03% 734
2020
Q3
$2.06M Sell
251,931
-42,275
-14% -$342K 0.03% 810
2020
Q2
$2.44M Sell
294,206
-19,888
-6% -$154K 0.03% 733
2020
Q1
$1.69M Sell
314,094
-10,397
-3% -$73K 0.03% 787
2019
Q4
$2.6M Sell
324,491
-2,260
-0.7% -$17.7K 0.03% 798
2019
Q3
$2.53M Buy
326,751
+58,567
+22% +$385K 0.04% 749
2019
Q2
$1.72M Buy
+268,184
New +$1.83M 0.02% 944

Other funds holding AKTS

Mutual of America Capital Management's AKTS Position: Q2 2022 in Review

Mutual of America Capital Management sold out of Akoustis Technologies Inc (AKTS) in Q2 2022, closing a stake of 280,643 shares — an estimated $1.82M sold.

Mutual of America Capital Management first reported a position in AKTS in Q2 2019 and held it in 12 quarters. The position peaked at $3.21M in Q2 2021. 136 funds tracked by Wall St. Rank hold AKTS as of Q2 2022.

  • Mutual of America Capital Management reported no remaining Akoustis Technologies Inc position as of Q2 2022 after selling out during the quarter.
  • Mutual of America Capital Management sold 280,643 Akoustis Technologies Inc shares in Q2 2022, an estimated $1.82M.
  • Mutual of America Capital Management first reported a position in Akoustis Technologies Inc in Q2 2019 and held it in 12 quarters.
  • Mutual of America Capital Management's Akoustis Technologies Inc position peaked at $3.21M in Q2 2021.
  • 136 funds tracked by Wall St. Rank held Akoustis Technologies Inc as of Q2 2022.

Based on Mutual of America Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.